Investigation of the performance of validated cardiovascular risk scores in a global (UK/US) cohort of young people with childhood-onset systemic lupus erythematosus

Coziana Ciurtin,Junjie Peng,Yiming Gao,Misato Niwa,Stacy P Ardoin,Laura Eve Schanberg,Laura Lewandowski,Elizabeth C Jury,George A Robinson

DOI: https://doi.org/10.1136/lupus-2024-001194

IF: 4.687

2024-06-14

Lupus Science & Medicine

Abstract:Chronic inflammation is one of the recognised drivers of increased cardiovascular disease risk (CVD-risk). Childhood-onset systemic lupus erythematosus (cSLE), characterised by onset before 18 years of age, has a more severe phenotype than adult-onset SLE and is associated with increased CVD-risk starting early in life. As a consequence of this increased risk, 4% of children and young people (CYP) with cSLE recruited to a large UK study experienced at least one CVD-event 2 years postdiagnosis, at a median age of 16 years.1 This suggests a critical unmet need for earlier identification of individuals with high CVD-risk for tailored risk management strategies in cSLE.2 Carotid intima-media thickness (CIMT) is one of the best predictors of CVD-risk across the life span. However, CVD-risk assessment guidelines recommend the evaluation of various traditional CVD-risk factors and use of CVD-risk scores, rather than vascular scans, for stratified management approaches in general population.3 The A therosclerosis P revention in P ediatric L upus E rythematosus (APPLE) trial, a large interventional clinical trial in cSLE, evaluated the efficacy of atorvastatin in decreasing atherosclerosis progression in CYP aged 10–18 years, using serial CIMT measurements.4 Although the trial did not meet the primary endpoint, it provided us with the opportunity to discover a novel serum metabolomic signature associated with a high rate of atherosclerosis progression in cSLE.5 As CIMT measurements on vascular scans are not routinely implemented in clinical practice, we explored the comparative performance of four age-appropriate and validated CVD-risk scores in a global cSLE (UK/US) cohort to address a key research priority identified by our PPIE activities. Demographic data, CVD-risk factors and cSLE characteristics were collected cross-sectionally from two cSLE cohorts: a retrospective University College London (UCL) cohort (N=109, UK) and ...

rheumatology